Article
GLP-1 Patents And Africa: The COVID-19 Lessons We Still Have Not Learned
Some debates appear to be new, yet from an intellectual property perspective, they follow a familiar pattern. Whenever a pharmaceutical breakthrough fundamentally changes the treatment of a widespread disease, the same question inevitably arises: how should the law balance the protection of innovation against the need to ensure access to essential medicines?
Inventa